One story that has everyone outraged is that of Turing Pharmaceuticals, run by a scoundrel -- by all accounts -- named Martin Shkreli. He took the price of the 62-year-old drug Daraprim, used to treat toxoplasmosis in HIV patients, and raised it to $750 a tablet. How is he getting away with this?
Of course, a chorus of commentators is screaming about vagaries of the "free market," "lax regulations." Shkreli whines, "This isn't the greedy drug company trying to gouge patients, it is us trying to stay in business." Who to believe? Maybe neither one.